CO5640085A2 - Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato - Google Patents

Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato

Info

Publication number
CO5640085A2
CO5640085A2 CO05125090A CO05125090A CO5640085A2 CO 5640085 A2 CO5640085 A2 CO 5640085A2 CO 05125090 A CO05125090 A CO 05125090A CO 05125090 A CO05125090 A CO 05125090A CO 5640085 A2 CO5640085 A2 CO 5640085A2
Authority
CO
Colombia
Prior art keywords
clavulanate
amoxicillin
approximately
amoxycline
pharmaceutical formulations
Prior art date
Application number
CO05125090A
Other languages
English (en)
Inventor
Michael Gale Ramsey
Jill Tracy Rickman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0313913.6A external-priority patent/GB0313913D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5640085A2 publication Critical patent/CO5640085A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Una formulación farmacéutica de amoxicilina y clavulanato proporcionada en forma de una composición en polvo seco adaptada para reconstitución con agua en una suspensión multidosis que comprende aproximadamente 600 mg de amoxicilina y aproximadamente 43 mg de clavulanato por cantidad unitaria de formulación, de modo que la relación de amoxicilina a clavulanato es aproximadamente 14: 1, y que comprende además un agente estabilizante del pH que es carboximetilcelulosa de sodio presente en de aproximadamente 20 a aproximadamente 60 mg por cantidad unitaria de formulación y excipientes farmacéuticamente aceptables.
CO05125090A 2003-06-16 2005-12-12 Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato CO5640085A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47876903P 2003-06-16 2003-06-16
GBGB0313913.6A GB0313913D0 (en) 2003-06-16 2003-06-16 New use

Publications (1)

Publication Number Publication Date
CO5640085A2 true CO5640085A2 (es) 2006-05-31

Family

ID=33420899

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05125090A CO5640085A2 (es) 2003-06-16 2005-12-12 Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato

Country Status (13)

Country Link
EP (1) EP1491195A1 (es)
JP (1) JP2006527726A (es)
KR (1) KR20060010838A (es)
AU (1) AU2004246811A1 (es)
BR (1) BRPI0411524A (es)
CA (1) CA2529102A1 (es)
CO (1) CO5640085A2 (es)
IL (1) IL172096A0 (es)
MA (1) MA27850A1 (es)
MX (1) MXPA05013433A (es)
NO (1) NO20055882L (es)
RU (1) RU2343931C2 (es)
WO (1) WO2004110441A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007002924A1 (de) * 2007-01-19 2008-07-24 Bayer Healthcare Ag ß-Lactam-haltige Formulierungen mit erhöhter Stabilität in wässriger Lösung
WO2013106601A1 (en) * 2012-01-10 2013-07-18 Michael Spector Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same
CN114668724B (zh) * 2020-12-24 2023-08-22 鲁南制药集团股份有限公司 一种阿莫西林克拉维酸钾干混悬剂及其制备方法
CN114886893B (zh) * 2021-07-30 2023-09-29 江苏恒丰强生物技术有限公司 一种复方阿莫西林粉及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975342B1 (en) * 1997-02-14 2003-06-25 Laboratoire GlaxoSmithKline S.A.S. Pharmaceutical formulations comprising amoxocyllin and clavulanate
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
US6977086B1 (en) * 1999-08-20 2005-12-20 Laboratorie Glaxosmithkline S.A.S. Pharmaceutical formulation comprising amoxycillin and clavulanate

Also Published As

Publication number Publication date
IL172096A0 (en) 2009-02-11
WO2004110441A1 (en) 2004-12-23
NO20055882L (no) 2005-12-28
EP1491195A1 (en) 2004-12-29
JP2006527726A (ja) 2006-12-07
AU2004246811A1 (en) 2004-12-23
RU2343931C2 (ru) 2009-01-20
MA27850A1 (fr) 2006-04-03
RU2005138127A (ru) 2006-07-27
BRPI0411524A (pt) 2006-08-01
WO2004110441A8 (en) 2005-03-17
MXPA05013433A (es) 2006-03-09
KR20060010838A (ko) 2006-02-02
CA2529102A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
BRPI0406996A (pt) Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
EA200500080A1 (ru) Дозированная форма прамипексола, принимаемая один раз в день
AR035195A1 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
AR019935A1 (es) Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
UY25544A1 (es) Forma de dosificación de nefazodona
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AP2003002763A0 (en) Controlled release formulations for oral administration
PE20011100A1 (es) Combinacion de amoxicilina y clavulanato de potasio
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
BR0012444A (pt) Composições de pó seco
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
BR0210224A (pt) Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR044697A1 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
TWI256309B (en) New formulation of mirtazapine

Legal Events

Date Code Title Description
FC Application refused